Multicenter, randomized, comparative, prospective study on efficacy of EVL-EVS sequential therapy in preventing esophageal variceal hemorrhage

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15005816

Enrollment

Unknown

Registered

2015-01-13

Start date

2015-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Variceal bleeding

Interventions

Group A:control group

Group B:EVL therapy

Group C:EVS therapy

Group D:EVL and EVS sequential therapy

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Written informed consent; 2. Subjects 18-65 of age; 3. With history of liver cirrhosis, endoscopy proved gastroesophageal varices exist and have indication of endoscopic therapy; 4. PTA more than at least 40%; 5. Without other complications of liver cirrhosis.

Exclusion criteria

Exclusion criteria: 1. With light to moderate esophageal varices; 2. With gastric varices; 3. PTA less than 40%; 4. Combined with malignant tumor of liver or other organs; 5. Cannot reach written informed consent.

Design outcomes

Primary

Measure	Time frame
5 years survival rate;	—

Secondary

Measure	Time frame
Esophageal varices bleeding rate;Rebleeding rate;Esophageal varices elimination rate;	—

Countries

China

Contacts

Public ContactBin Wu

binwu001@hotmail.com+86 18922103388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026